Kedrion Biopharma Announces The Extension Of A U.S. Agreement With Grifols To Support Long-Term And Continued Access To Gammaked®
GRFS•Agreement extension supports access to Gammaked
Grifols, S.A. GRLS.MC:
- Kedrion Biopharma announces the extension of a U.S. agreement with Grifols to support long-term and continued access to Gammaked®.
- Kedrion Biopharma says the deal maintains key therapies within Kedrion's U.S. immunodeficiency and auto immune disorders portfolio.
Source text: ID:nPn32hylKa
Further company coverage: GRLS.MC
